NCT00042679View on ClinicalTrials.gov

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2002

Conditions

Carcinoma, Non-Small-Cell LungPulmonary NeoplasmsNeoplasms, Lung

Interventions

DRUG

Gemcitabine

DRUG

Carboplatin

DRUG

LY900003

Trial Locations (11)

Unknown

Bakersfield

Berkeley

Torrance

Miami Beach

Chicago

Park Ridge

Baltimore

Chattanooga

Lubbock

Charlottesville

Milwaukee

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00042679 - A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter